Pancreatic Cancer Diagnostic Market Report
The Global Pancreatic Cancer Diagnostic Market is segmented by Treatment (Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy), By Test (Imaging Test, Biopsy, Blood test), By End User (Hospitals, Clinics, Research Institutes), and Region. The report also covers the COVID-19 Impact Analysis and Forecast to 2026. This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Pancreatic Cancer Diagnostic market. The historic years considered for the study are 2016-2019, the base year is 2020, estimated year is 2021, and forecast period is 2022-2026.
The Global Pancreatic Cancer Diagnostic Market is segmented by Treatment (Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy), By Test (Imaging Test, Biopsy, Blood test), By End User (Hospitals, Clinics, Research Institutes), and Region...
Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.
Note: The summary below might not have included insights on covid impact since we have large number of reports.
The Global Pancreatic Cancer Diagnostic Market is estimated to grow from USD 2.4 billion in 2020 to USD 3.5 billion by 2026 at a healthy CAGR of 6.7% during the forecast period.
Figure: Global Pancreatic Cancer Diagnostic Market Size, 2020-2026 (USD Billion)
Wish to get a sample report? Click here.
Pancreatic cancer is defined as a type of cancer that occurs within the tissues of the pancreas. The pancreas is located behind the stomach and it aids in digestion by producing enzymes needed by the body to digest fats, proteins, and carbohydrates.
It also produces hormones that control blood sugar levels in the body. It can be diagnosed using various tests including CT scan, magnetic resonance imaging, biopsy, and blood test among others.
The key players operating in the global Pancreatic Cancer Diagnostic market are-
The global market growth is primarily driven by the rising number of people having pancreatic cancer due to obesity, high consumption of alcohol, and smoking.
Based on the test, the market has been divided into imaging test, biopsy, blood test and other.
The imaging segment accounted for the largest share in 2020 and is expected to continue its dominance during the review period as it helps to detect cancer at an early stage. The biopsy segment is projected to register healthy growth during the review period.
The market in North America accounted for the largest share in 2020 owing to rising incidences of pancreatic cancer, expanding geriatric population, and availability of advanced diagnosis solutions.
The market in the Asia-Pacific region is projected to register a healthy growth rate on account of an increasing number of people having pancreatic cancer couples with the availability of advanced treatment facilities.
The covid-19 outbreak did affect the growth of the pancreatic cancer diagnostic market negatively as patients suffering for pancreatic cancer postponed their surgery due to rapid surge in covid-19 cases across geographies. Additionally, people having pancreatic cancer were at risk of becoming severely ill. The fear of corona virus infection affected the growth of the pancreatic cancer diagnostic market amid pandemic.
Wish to get a full scope of the report? Click here.
The following is a list of the customers that the Global Pancreatic Cancer market aims to convert the most:
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
The pancreatic cancer diagnostic market size is expected to reach USD 3.5 billion in the foreseeable future.
F. Hoffmann-La Roche AG (Switzerland), Myriad Genetics (The U.S), GE Healthcare (The U.S), BD (India), Koninklijke Philips N.V. (Netherlands), Siemens AG (Germany), Abbott Laboratories (The U.S), Hitachi Medical Corporation (Japan), Canon Medical Systems Corporation (Japan), Danaher Corporation (The U.S), Qiagen (Germany), BioMarker Strategies (The U.S) and Asuragen, Inc. (The U.S) are among the key players in the pancreatic cancer diagnostic market.
The pancreatic cancer diagnostic market is expected to witness an impressive growth of 6.7% CAGR in the coming years.
North America accounted for the largest share of pancreatic cancer diagnostic market in 2020.
The imaging segment is expected to remain dominant in the pancreatic cancer diagnostic market in the coming years.
Rising number of people having pancreatic cancer, expand geriatric population, increasing investment in research and development activities to develop advanced diagnostic solutions are the factors driving the growth of pancreatic cancer diagnostic market.
Pancreatic cancer diagnostic distributors, Pancreatic cancer diagnostic suppliers, Pancreatic cancer diagnostic manufacturers, Logistics organizations, Government Bodies are the target audience in the pancreatic cancer diagnostic market.